Role of K-ras (codon 13) mutation in ovarian carcinoma

EGFR is a cell surface receptor involved in various cell signaling pathway resulting in cell growth, proliferation and metastasis. Upon binding to ligand, receptor dimerization and internalization leads to phosphorylation of internal domain of receptor and activation of signaling cascade. Anti EGFR antibodies are new and efficient theraputics for cancers with high level expression of EGFR, but it has shown that cancers with mutated k-ras are resistant to these class of therapeutics. Determination of mutation in K-ras gene is important in predicting response to AntiEGFR therapies. The aim of this study was to determine the frequency of mutation in codon 13 of Kras gene in patients with ovarian cancers. Methods:To estimate the prevalence of codon 13, The DNA was extracted from paraffin embedded tissues and subjected to k-ras mutation analysis by nested PCR and RFLP analysis. Result: Analysis of nested-PCR and RFLP results revealed that none of 40 patients had mutation in codon 13. Conclude:The results of this study show that mutation in codon 13 is uncommon in patients with ovarian cancers in the study region. patients with k-ras wild type in codon 12 ,without testing codon 13, may benefit from treatment with anti-EGFR therapy.

کلیدواژه ها:

mutation ، k-ras ، codon 13 ، ovarian cancer